Clinical Profile and Genomic Mutational Landscape of Prostate Cancer in Brunei Darussalam from 2018 to 2024 A Retrospective Descriptive Study
Background Prostate cancer has become one of the leading causes of malignancy affecting men in Brunei Darussalam, with steadily rising incidence over the past decade. However, its clinical, pathological, and molecular characteristics remain poorly described. This study aims to address this knowledge gap by providing a detailed profile of prostate cancer's clinical and genomic profile in the country. Methods In this retrospective cohort study, medical records of 212 prostate cancer patients receiving 478 treatments received between January 2018 and December 2024 at The Brunei Cancer Centre (TBCC), Jerudong Park Medical Centre (JPMC) were analyzed. Demographic, clinical, laboratory, treatment and genomic data were extracted from BruHIMS,laboratory records, clinical notes, and Next Generation Sequencing report. Data was processed and analyzed using RStudio version 4.3.3 and Python 3.10 (Google Colab) following the STROBE checklist. Results Most patients were aged 71–80 years (39.15%), of Malay ethnicity (63.73%), and presented with advanced-stage disease (65%), with frequent metabolic comorbidities; 80% were alive with median survival follow up of 2.25 years. Nearly one-third underwent NGS, revealing diverse genomic alterations, including actionable DDR-related mutations. Median baseline PSA was high (11.1ng/mL, IQR 1.2–85.5), declining to (0.54 ng/mL, IQR 0.07–4.83) post-treatment. Treatment modality showed significant difference between age (p < 0.001), marital status (p < 0.001), survival status (p < 0.001), disease severity (p < 0.001), PSA level (p < 0.001), and several haematological and biochemical parameters. The younger patients (50–60 years) had the highest body weight with late-stage presentation, indicating an emerging metabolic risk profile in this subgroup. Conclusion This study offers the first comprehensive clinical and genomic profile of prostate cancer in Brunei, highlighting the urgent need for earlier detection, broader genomic testing, and tailored management strategies. The dataset lays a robust foundation for developing AI-driven precision oncology tools to improve outcomes for prostate cancer patients.
Authors
- Owais Ahmed Malik (ORCID: https://orcid.org/0000-0002-4888-5448)
- Hanif Abdul Rahman (ORCID: https://orcid.org/0000-0003-3022-8690)
- Ummi Salwa Suhaimei (ORCID: https://orcid.org/0009-0009-9004-2127)
- Lin Naing (ORCID: https://orcid.org/0000-0003-1723-9854)
- Muhammad Abdullah (ORCID: https://orcid.org/0009-0004-7050-4033)
- Hein Minn Tun (ORCID: https://orcid.org/0000-0003-4277-8251)
- Thu Ta
Institutions
- Universiti Brunei Darussalam (BN)
- Atlantic Technological University (IE)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-18
- DOI
- https://doi.org/10.21203/rs.3.rs-11550574/v1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- preprint